Roth Capital Maintains Buy On PTC Therapeutics Ahead Of 3Q14 Financial Results
In a research note published Friday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on PTC Therapeutics (NASDAQ:PTCT) with a $58 price, as the company will report 3Q14 financial results and provide an update on the company’s business and outlook on Thursday, November 6, 2014.
Chattopadhyay said, “We anticipate additional color on launch timings, reimbursement decisions, and pricing from key territories including Germany, France, the UK and Scandinavia. Additionally, we anticipate clarity on the company’s strategy to rapidly screen and identify DMD patients and its ongoing efforts to roll over clinical study patients to its commercial arm. Recall that Translarna had a robust, statistically-significant benefit in nmCF patients not being treated with aminoglycosides, and a large well-powered phase 3 is underway. We anticipate updates on enrollment because it could be the rate limiting factor in submitting the abbreviated filing for conditional approval in the EU. A potential conditional approval for nmCF could have meaningful revenue implications for 2016.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -9.0% and a 43.5% success rate. Chattopadhyay has a 10.1% average return when recommending PTCT, and is ranked #3246 out of 3343 analysts.